CHARM Therapeutics launches with a $50 million Series A financing

UK-based deep-learning research company discovering and developing transformational medicines CHARM Therapeutics today announced today a $50 million Series A financing co-led by F-Prime Capital and OrbiMed, with General Catalyst, Khosla Ventures, Braavos, Grep VC and Axial also participating.

CHARM Therapeutics is pioneering end-to-end 3D deep-learning to discover and develop transformational medicines against previously hard-to-drug targets. The company’s proprietary platform, DragonFold, applies expertise in protein-ligand co-folding to deliver transformational medicines targeting challenging molecular targets in cancer and other disease areas.

CHARM Therapeutics was co-founded by Laksh Aithani, who previously founded Y Combinator-backed genei, and was a core contributor to the machine learning platform at Exscientia and most recently was Entrepreneur in Residence at Braavos. He will serve as CHARM’s chief executive. David Baker, head of the Institute for Protein Design, University of Washington, is co-founder.